Published in Sci Rep on July 27, 2016
The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol (2017) 0.77
Managing the sequence-specificity of antisense oligonucleotides in drug discovery. Nucleic Acids Res (2017) 0.75
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat Genet (2006) 5.26
RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol (2010) 4.86
Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol Cell (2007) 2.71
Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development. Cell (2012) 2.62
Failure to produce mitochondrial DNA results in embryonic lethality in Rnaseh1 null mice. Mol Cell (2003) 2.60
Enzymatic completion of mammalian lagging-strand DNA replication. Proc Natl Acad Sci U S A (1994) 2.11
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation (2006) 2.08
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res (2006) 1.98
RNase H and postreplication repair protect cells from ribonucleotides incorporated in DNA. Mol Cell (2012) 1.74
Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem (2004) 1.68
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res (2010) 1.67
Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol (2009) 1.66
Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity. J Exp Med (2012) 1.62
Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem (2009) 1.61
Acyl-CoA synthesis, lipid metabolism and lipotoxicity. Biochim Biophys Acta (2009) 1.58
Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition. J Biol Chem (2009) 1.54
Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol (2007) 1.53
Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc (2014) 1.31
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos (2006) 1.27
Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J Biol Chem (2004) 1.22
Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol Pharmacol (2006) 1.18
The structure of the human RNase H2 complex defines key interaction interfaces relevant to enzyme function and human disease. J Biol Chem (2010) 1.17
Chemical modification study of antisense gapmers. Nucleic Acid Ther (2012) 1.13
An upstream open reading frame and the context of the two AUG codons affect the abundance of mitochondrial and nuclear RNase H1. Mol Cell Biol (2010) 1.07
Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3'-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides. J Am Chem Soc (2011) 1.02
Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet (2009) 1.02
Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis (2013) 1.00
Functional alterations of liver innate immunity of mice with aging in response to CpG-oligodeoxynucleotide. Hepatology (2008) 1.00
An exocyclic methylene group acts as a bioisostere of the 2'-oxygen atom in LNA. J Am Chem Soc (2010) 0.99
Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides (2004) 0.96
Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther (2013) 0.95
Enhanced base pairing and replication efficiency of thiothymidines, expanded-size variants of thymidine. J Am Chem Soc (2006) 0.94
Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides. Nucleic Acids Res (2014) 0.94
Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther (2005) 0.93
Biological activity and biotechnological aspects of locked nucleic acids. Adv Genet (2013) 0.93
Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat Biotechnol (2012) 0.92
Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther (2013) 0.91
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res (2015) 0.88
Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals. Mol Ther Nucleic Acids (2012) 0.86
In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res (2015) 0.84
Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. Metabolism (2005) 0.84
Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice. Toxicol Sci (2013) 0.83
The role of transporters in the toxicity of nucleoside and nucleotide analogs. Expert Opin Drug Metab Toxicol (2012) 0.82
Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response. J Pharmacol Exp Ther (2012) 0.81
Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B. J Pharmacol Exp Ther (2016) 0.76